Novavax
About
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
- Gaithersburg,Maryland,United States
- 1001 - 5000
- http://www.novavax.com
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $175.25M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1987
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
- Stock Symbol
- nasdaq:NVAX
- Legal Name
- Novavax AB
- Also Known As
- Isconova,Molecular Packaging Systems
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 15, 2022 | Post-IPO Equity | $74.75M | — | — | — | Detail |
| Dec 14, 2022 | Post-IPO Debt | $175.25M | — | — | — | Detail |
| Jul 7, 2020 | Grant | $1.60B | 1 |
Government of United States of America
|
— | Detail |
| Jun 15, 2020 | Post-IPO Equity | $200M | 1 |
RA Capital Management
|
— | Detail |
| May 11, 2020 | Grant | $384M | 1 |
Coalition for Epidemic Preparedness Innovations
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Government of United States of America
|
Yes | Grant |
|
RA Capital Management
|
Yes | Post-IPO Equity |
|
Coalition for Epidemic Preparedness Innovations
|
Yes | Grant |
Bill & Melinda Gates Foundation
|
— | Grant |
Innovations Kapital
|
— | Post-IPO Equity |
Employee Profiles
Acquisition
Novavax has acquired 1 organizations. Their most recent acquisition was Isconova AB on Dec 2, 2013. They acquired Isconova AB for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Dec 2, 2013
Isconova AB
|
Biotechnology | acquisition | — | Detail |
